FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (I), where R, L, X, Y, m are defined in the claims, and pharmaceutical compositions containing it, designed to modulate the fibroblast activation protein (FAP).
(I)
EFFECT: compounds and compositions can be used as medicinal products for the treatment of diseases or disorders mediated by fibroblast activation protein (FAP), including hyperproliferative diseases.
32 cl, 3 dwg, 6 tbl, 47 ex
Title | Year | Author | Number |
---|---|---|---|
ACTIVE COMPOUNDS WITH RESPECT TO BROMO-DOMAINS | 2015 |
|
RU2743074C2 |
ANTIVIRAL REMEDIES FOR TREATMENT AND PREVENTION OF HIV INFECTION | 2021 |
|
RU2780103C1 |
PYRAZOLOPYRIMIDINE-BASED JAK INHIBITING COMPOUNDS AND METHODS | 2010 |
|
RU2567238C2 |
INHIBITING JAK COMPOUNDS BASED ON PYRAZOLOPYRIMIDINE AND METHODS | 2010 |
|
RU2675857C2 |
CYCLIC CYANOENONE DERIVATIVES AS KEAP1 MODULATORS | 2021 |
|
RU2822828C1 |
ANTIVIRAL REMEDIES FOR TREATMENT AND PREVENTION OF HIV INFECTION | 2020 |
|
RU2780101C2 |
SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE FOR TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2773333C2 |
CHEMICAL COMPOUNDS | 2018 |
|
RU2800292C2 |
DIAZONIUM AMIDE ANALOGUES | 2012 |
|
RU2608308C2 |
BICYCLIC AGONISTS OF THE INTERFERON GENE STIMULATOR STING | 2020 |
|
RU2800072C1 |
Authors
Dates
2023-08-28—Published
2020-01-03—Filed